• Vyome Holdings posted a net loss attributable to common shareholders of $963,000, or $0.15 per share, for Q1 ended March 31, 2026.
• Revenue fell to $31,591 from $198,581 a year earlier, while operating expenses jumped to $1.1 million from $353,417.
• Cash and cash equivalents climbed to $8.8 million from $5 million at Dec. 31, 2025, following a $5.29 million common-share sale.
• VT-1953 advanced toward pivotal-stage readiness with FDA discussions; an Orphan Drug Designation application was filed for malignant fungating wounds.
• Management highlighted a debt-free capital structure; VT-1953 Phase 2 data were presented at AACR 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260528750612) on May 28, 2026, and is solely responsible for the information contained therein.